Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.

J Transl Med · 2010 · PMC2903523 · PMID 20529245

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Comparison of pre- and post-Her2-pDNA vaccine responses in patients evaluable at all time points showed a trend towards higher mean binding activity of post- versus pre-vaccination sera against Her2 (Figure 3A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.